AR and prostate cancer: Treating the prostate cancer cells with proteasome inhibitor MG132 averted VNPP433-3β-induced degradation of AR but lead to accumulation of ubiquitinated f-AR and AR-V7, potentially due to f-AR hetero-dimerization (f-AR and AR-V7) as previously described [32].